Clinical Trials
2 trialsNCT05713110 2025-01-22
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Hutchmed
Phase 2 Completed
NCT02220842 2020-01-27
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed